NBSE News and Press, NeuBase Therapeutics Inc. From 05/20/21

PITTSBURGH, May 20, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of precision genetic medicines, today announced the appointment of Sandra Rojas-Caro, M.D., as C...

RBC Capital Markets Virtual Global Healthcare Conference Fireside Chat at 11:30 a.m. ET on May 19 Oppenheimer Rare & Orphan Disease Summit presentation on May 21 PITTSBURGH, May 14, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBa...

NeuBase Therapeutics (NBSE): Q1 GAAP EPS of -$0.24.The Company had cash and cash equivalents of approximately $24.2 million.Press Release For further details see: NeuBase Therapeutics reports Q1 results

Extended cash runway into CY2023 following completion of an equity financing from leading healthcare investors generating $42.6 million in net proceeds; supports advancing the Company’s lead program into the clinic and scaling of its precision genetic medicine pipeline Co...

Professional dealmaker operating across the healthcare continuum to bring together key partners to translate scientific breakthroughs into commercial applications for the benefit of patients and society Creator and guide of strategic alliances, including TGen, MMRC, and CIRM, ...

PITTSBURGH, April 27, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology company accelerating the genetic revolution with a new class of precision genetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive O...

NeuBase Therapeutics (NBSE) prices an underwritten public offering of 8M shares of its common stock, at a price to the public of $5.00 per share; gross proceeds $40M.Underwriters' 30-day option to purchase up to an additional 1.2M shares.Net proceeds to be used for general corporate purp...

PITTSBURGH, April 22, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology company accelerating the genetic revolution with a new class of precision genetic medicines, announced today the pricing of an underwritten public offering of ...

Evolus (EOLS) -19% after prices equity offering at $9.50.NeuBase Therapeutics (NBSE) -15% on launching stock offeringFisker (FSR) -10% after Goldman Sachs turns bearishCredit Suisse Group (CS) -5% on Q1 earnings release For further details see: Cr...

NeuBase Therapeutics (NBSE) trades 6.7% down after hours on commencing an underwritten public offering of shares; underwriters granted 30-day option to purchase up to an additional 15% of the shares.Offer size, terms have not been disclosed.Net proceeds to be used for general c...